5- CRIMM – PUBBLICAZIONI

1 - CRIMM Chi siamo e dove siamo
2 - Le Malattie Mieloproliferative
3 - Attività clinica e diagnostica di laboratorio
4 - Clinical Trial Unit CRIMM
5 - Pubblicazioni

Pubblicazioni ultimi 3 anni


Vannucchi AM, Guglielmelli P. Traffic lights for ruxolitinib.


Ruberti S, Bianchi E, Guglielmelli P, et al. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.


Harrison CN, Vannucchi AM, Kiladjian JJ et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.


Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms.

Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available
Vannucchi AM. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.
Koschmieder S, Mughal TI, Hasselbalch HC, et al. Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both.
cells by next generation sequencing in metastatic breast cancer.


Barbui T, Vannucchi AM, Carobbio A, et al. Patterns of presentation and thrombosis outcome in patients with Polycythemia Vera strictly defined by WHO-criteria and stratified


Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis.


Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.


Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

and Hematological Phenotype and Outcome in Essential Thrombocythemia.


Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.


Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera.


Martinelli I, De Stefano V, Carobbio A, et al. Cerebral vein thrombosis in patients with...


Vannucchi AM. How I treat Polycythemia vera.


Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis.


Verstovsek S, Passamonti F, Rambaldi A, et al. Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea.